A cohort study of MFN2 mutations and phenotypic spectrums in Charcot-Marie-Tooth disease 2A patients

被引:35
|
作者
Choi, B-O [1 ]
Nakhro, K. [2 ]
Park, H. J. [2 ]
Hyun, Y. S. [2 ]
Lee, J. H. [2 ]
Kanwal, S. [3 ]
Jung, S-C. [4 ]
Chung, K. W. [2 ]
机构
[1] Sungkyunkwan Univ, Dept Neurol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[2] Kongju Natl Univ, Dept Biol Sci, Kong Ju 314701, Chungnam, South Korea
[3] COMSATS Inst Informat Technol, Dept Biosci, Sahiwa, Pakistan
[4] Ewha Womans Univ, Mokdong Hosp, Dept Biochem, Sch Med, Seoul 158710, South Korea
关键词
Charcot-Marie-Tooth disease 2A; exome; genotype-phenotype correlation; Korean; mitofusin; 2; GENETIC SUBTYPES; OPTIC ATROPHY; MITOFUSIN-2; NEUROPATHY; MITOCHONDRIA; POPULATION; FREQUENCY; FAMILIES; TYPE-2;
D O I
10.1111/cge.12432
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Charcot-Marie-Tooth disease 2A (CMT2A) is the most common axonal form of peripheral neuropathy caused by a defect in the mitofusin 2 (MFN2) gene, which encodes an outer mitochondrial membrane GTPase. MFN2 mutations result in a large range of phenotypes. This study analyzed the prevalence of MFN2 mutation in Korean families with their assorted phenotypes (607 CMT families and 160 CMT2 families). Direct sequencing of the MFN2 coding exons or whole-exome sequencing has been applied to identify causative mutations. A total of 21 mutations were found in 36 CMT2 families. Comparative genotype-phenotype correlations impacting severity, onset age, and specific symptoms were assessed. Most mutations were seen in the GTPase domain (approximate to 86%). A deletion mutation found in the transmembrane helices is reported for the first time, as well as five novel mutations at other domains. MFN2 mutations made up 5.9% of total CMT families, whereas 22.9% in CMT2 families, of which 27.8% occurred de novo. Interestingly, patient phenotypes ranged from mild to severe even for the same mutation, suggesting other factors influenced phenotype and penetrance. This CMT2A cohort study will be useful for molecular diagnosis and treatment of axonal neuropathy.
引用
收藏
页码:594 / 598
页数:5
相关论文
共 50 条
  • [21] INF2 mutations in patients with a broad phenotypic spectrum of Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis
    Park, Jin Hee
    Kwon, Hye Mi
    Nam, Da Eun
    Kim, Hye Jin
    Nam, Soo Hyun
    Kim, Sang Beom
    Choi, Byung-Ok
    Chung, Ki Wha
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2023, 28 (01) : 108 - 118
  • [22] MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families
    Braathen, Geir J.
    Sand, Jette C.
    Lobato, Ana
    Hoyer, Helle
    Russell, Michael B.
    BMC MEDICAL GENETICS, 2010, 11
  • [23] Adenine nucleotide translocase is involved in a mitochondrial coupling defect in MFN2-related Charcot-Marie-Tooth type 2A disease
    Guillet, Virginie
    Gueguen, Naig
    Verny, Christophe
    Ferre, Marc
    Homedan, Chadi
    Loiseau, Dominique
    Procaccio, Vincent
    Amati-Bonneau, Patrizia
    Bonneau, Dominique
    Reynier, Pascal
    Chevrollier, Arnaud
    NEUROGENETICS, 2010, 11 (01) : 127 - 133
  • [24] Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives
    Alberti, Claudia
    Rizzo, Federica
    Anastasia, Alessia
    Comi, Giacomo
    Corti, Stefania
    Abati, Elena
    NEUROBIOLOGY OF DISEASE, 2024, 193
  • [25] An integrative analysis of genotype-phenotype correlation in Charcot Marie Tooth type 2A disease with MFN2 variants: A case and systematic review
    Zhang, Yuanzhu
    Pang, Daxin
    Wang, Ziru
    Ma, Lerong
    Chen, Yiwu
    Yang, Lin
    Xiao, Wenyu
    Yuan, Hongming
    Chang, Fei
    Ouyang, Hongsheng
    GENE, 2023, 883
  • [26] Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations
    Amiott, Elizabeth A.
    Lott, Paul
    Soto, Jamie
    Kang, Peter B.
    McCaffery, J. Michael
    DiMauro, Salvatore
    Abel, E. Dale
    Flanigan, Kevin M.
    Lawson, Victoria H.
    Shaw, Janet M.
    EXPERIMENTAL NEUROLOGY, 2008, 211 (01) : 115 - 127
  • [27] Mutation Analysis of MFN2, GJB1, MPZ and PMP22 in Italian Patients with Axonal Charcot-Marie-Tooth Disease
    Bergamin, Giorgia
    Boaretto, Francesca
    Briani, Chiara
    Pegoraro, Elena
    Cacciavillani, Mario
    Martinuzzi, Andrea
    Muglia, Maria
    Vettori, Andrea
    Vazza, Giovanni
    Mostacciuolo, Maria Luisa
    NEUROMOLECULAR MEDICINE, 2014, 16 (03) : 540 - 550
  • [28] POLG mutations presenting as Charcot-Marie-Tooth disease
    Phillips, Jade
    Courel, Steve
    Rebelo, Adriana P.
    Bis-Brewer, Dana M.
    Bardakjian, Tanya
    Dankwa, Lois
    Hamedani, Ali G.
    Zuchner, Stephan
    Scherer, Steven S.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2019, 24 (02) : 213 - 218
  • [29] INF2 Mutations in Charcot-Marie-Tooth Disease with Glomerulopathy
    Boyer, Olivia
    Nevo, Fabien
    Plaisier, Emmanuelle
    Funalot, Benoit
    Gribouval, Olivier
    Benoit, Genevieve
    Cong, Evelyne Huynh
    Arrondel, Christelle
    Tete, Marie-Josephe
    Montjean, Rodrick
    Richard, Laurence
    Karras, Alexandre
    Pouteil-Noble, Claire
    Balafrej, Leila
    Bonnardeaux, Alain
    Canaud, Guillaume
    Charasse, Christophe
    Dantal, Jacques
    Deschenes, Georges
    Deteix, Patrice
    Dubourg, Odile
    Petiot, Philippe
    Pouthier, Dominique
    Leguern, Eric
    Guiochon-Mantel, Anne
    Broutin, Isabelle
    Gubler, Marie-Claire
    Saunier, Sophie
    Ronco, Pierre
    Vallat, Jean-Michel
    Angel Alonso, Miguel
    Antignac, Corinne
    Mollet, Geraldine
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (25) : 2377 - 2388
  • [30] Dynamin 2 in Charcot-Marie-Tooth Disease
    Tanabe, Kenji
    Takei, Kohji
    ACTA MEDICA OKAYAMA, 2012, 66 (03) : 183 - 190